Doepker et al identified risk factors associated with argatroban therapy in a patient in the intenstive care unit (ICU). These can help to identify patients who may require closer monitoring or dosage adjustment. The authors are from the Ohio State University.
Patient selection: ICU patient receiving argatroban
Parameters:
(1) major surgery before or during argatroban therapy
(2) dosing weight in kilograms
(3) total serum bilirubin in mg/dL
(4) platelet count
Parameter |
Finding |
Points |
major surgery |
no |
0 |
|
yes |
1 |
dosing weight |
<= 90 kg |
0 |
|
> 90 kg |
1 |
total serum bilirubin |
< 3 mg/dL |
0 |
|
>= 3 mg/dL |
1 |
platelet count |
> 70,000 per µL |
0 |
|
<= 70,000 per µL |
1 |
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum number of risk factors: 0
• maximum number of risk factors: 4
• The risk of bleeding increases with the number of risk factors present.
The paper assumes that the patient's argatroban dose was adjusted for renal and hepatic function. Failure to reduce the dose for renal or hepatic dysfunction would increase risk of bleeding as well.
Specialty: Hematology Oncology, Clinical Laboratory, Pharmacology, clinical